A Phase 2 Extension Trial of the Safety and Immunogenicity of Cytomegalovirus mRNA-1647 Vaccine Through 36 Months in Healthy Adults

Category Primary study
ConferenceInfectious Diseases Society for Obstetrics and Gynecology Annual Meeting, IDSOG 2025
Year 2025
This article has no abstract
Epistemonikos ID: 8c051615a5be025c07cc1a4ae2cc26031c4269f4
First added on: Feb 21, 2026